Fierce Pharma
AUGUST 11, 2023
It’s been a rough summer for pharmaceutical companies trying to resolve lawsuits by declaring bankruptcy. | The Supreme Court has halted Purdue Pharma’s $6-billion bankruptcy settlement, which granted the company’s former owners—the Sackler family—immunity from civil suits related to the opioid crisis.
PharmExec
AUGUST 11, 2023
How pharma medical affairs and commercial teams are synchronizing their capabilities to boost omnichannel marketing strategies and better understand customer engagement needs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
AUGUST 11, 2023
Ceribell Inc., based in Sunnyvale, California, has developed a point-of-care EEG system that provides real-time seizure monitoring and alerting, which helps in the rapid and precise treatment of patients with suspected non-convulsive seizures. The FDA-cleared Ceribell ClarityPro software uses a machine-learning model to analyze EEG signals and generate bedside alerts.
European Pharmaceutical Review
AUGUST 10, 2023
The US Food and Drug Administration (FDA) has granted accelerated approval of TALVEY (talquetamab-tgvs) to treat multiple myeloma. Janssen Pharmaceutical Companies of Johnson & Johnson’s first-in-class bispecific T-cell engaging antibody showed an overall response rate (ORR) of over 70 percent in heavily pre-treated multiple myeloma. Based on this data, TALVEY is indicated for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, includin
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
AUGUST 11, 2023
Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) drug Relyvrio continues to wow Wall Street. | Amylyx’s amyotrophic lateral sclerosis drug Relyvrio continues to wow Wall Street. The drug brought in $98.2 million revenue in the second quarter, handily beating analysts’ consensus estimates of below $92 million.
PharmExec
AUGUST 11, 2023
From public defender to spearheading the adoption of innovative drugs, Wendy Short Bartie, senior VP and general manager for the hematology and cell therapy division at Bristol Myers Squibb, has remained a steadfast patient advocate—working to fulfill unmet medical needs and bring treatments to as many people as possible.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Technology
AUGUST 11, 2023
Following the business expansion in 2022, Clinigen announced the divestment of four of its cancer therapies.
Fierce Pharma
AUGUST 11, 2023
Less than a month after the family of Henrietta Lacks reached a settlement with Thermo Fisher over its use of Lacks’ cells, another drugmaker stands accused of profiting from a racist medical syste | Less than a month after the family of Henrietta Lacks reached a settlement with Thermo Fisher over its use of Lacks’ cells, another drugmaker stands accused of profiting from a racist medical system.
Eversana Intouch
AUGUST 10, 2023
The industry challenges faced in marketing in the rare disease space are not new. Small populations. Limited understanding of the patient or disease. Diagnostic odysseys that last, on average, seven years and are riddled with misdiagnosis. What is new, however, is the opportunity. At EVERSANA INTOUCH, our rare expertise and advanced technologies are helping solve some of the most difficult challenges in rare disease marketing.
MedCity News
AUGUST 10, 2023
This week, virtual care company Babylon Health permanently closed its U.S. operations and laid off 94 employees. The news came after the company’s rescue merger fell apart — Babylon had planned to go private through a deal with Swiss digital therapeutics firm MindMaze and Babylon creditor AlbaCore Capital.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PM360
AUGUST 9, 2023
Real Chemistry , a leading provider of AI-driven insights and marketing and communications for the healthcare industry, is partnering with WhizAI , a generative AI-powered analytics platform purpose-built for life sciences and healthcare, to develop a patient journey visualization and analytics solution. This new platform promises to make it easier for clients to access accurate, contextual insights by asking conversational questions while also having the ability to visualize the process patient
Fierce Pharma
AUGUST 11, 2023
Bristol Myers Squibb has laid off more than 100 employees amid a reconfiguration of expenses that follows disappointing earnings results. | Bristol Myers Squibb has laid off more than 100 employees amid a reconfiguration of expenses that follows disappointing earnings results.
Pharmaceutical Technology
AUGUST 9, 2023
Eli Lilly and Company has posted reported net income of $1.76bn in the second quarter (Q2) of 2023 as against $952.5m in Q2 2022.
MedCity News
AUGUST 10, 2023
In the future, research in personalized nutrition needs to focus on understanding the role of nutrition throughout the entire lifespan and address diet-related conditions through comprehensive interventions that go beyond simply choosing healthy foods.
European Pharmaceutical Review
AUGUST 9, 2023
According to research from GlobalData, the pharmaceutical industry is shifting towards development of antibody-drug conjugates (ADC) as oncology treatments. The data showed that Daiichi Sankyo , Seagen and Roche are currently three of the most important companies in the ADC market. Daiichi Sankyo was predicted to remain the dominant player in this market.
Fierce Pharma
AUGUST 10, 2023
After Pfizer allegedly fired a compliance manager for raising the flag on potential fraud activity in China, the former employee is hitting back. | Frank Han, Pfizer's former director of global compliance analytics, has filed a civil complaint against the drugmaker. Han claims he was terminated for identifying potential issues relating to the Foreign Corrupt Practices Act.
PharmExec
AUGUST 11, 2023
Continued approval to be based on verification and description of clinical benefit in confirmatory trials.
MedCity News
AUGUST 10, 2023
Johnson & Johnson’s stable of multiple myeloma drugs has grown to five products with the FDA approval of Talvey. The bispecific antibody is the first in a new class of new drugs designed to go after the novel multiple myeloma target GPRC5D.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaVoice
AUGUST 9, 2023
Children’s Tumor Foundation president Annette Bakker is working to teach the industry the crucial difference between drug repurposing and drug repositioning.
Fierce Pharma
AUGUST 10, 2023
Johnson & Johnson is digging its multiple myeloma moat deeper thanks to FDA approval for another novel drug. | Johnson & Johnson is digging its multiple myeloma moat deeper. The FDA has signed off on the company's Talvey, a first-in-class bispecific antibody targeting GPRC5D.
Pharmaceutical Technology
AUGUST 10, 2023
AI is essential in drug discovery and development and a growing number of start-ups now operate in this area
MedCity News
AUGUST 11, 2023
An AI-driven app called juli improved symptoms of asthma and depression, two randomized controlled trials found. The app takes in data from electronic medical records, smartphones, wearable devices, the environment and patient questionnaires to provide personalized health recommendations.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
PharmExec
AUGUST 10, 2023
Hernandez details how the non-profit organization advocates for improved access to care at the community, state, and federal levels, and amplifies education and awareness efforts within its social media communities.
Fierce Pharma
AUGUST 10, 2023
As Regeneron anxiously awaits an FDA decision on a high-dose version of Eylea (aflibercept), the company has continually referred to its durability compared to that of Roche’s upstart Vabysmos—whic | As Regeneron anxiously awaits an FDA decision on a high-dose version of Eylea (aflibercept), the company has continually referred to its staying power compared to that of Roche’s upstart Vabysmos—which has taken the macular degeneration (AMD) market by storm since receiving approval 19 months ago.
European Pharmaceutical Review
AUGUST 8, 2023
Headline results from Novo Nordisk’s “landmark” SELECT trial in cardiovascular outcomes has demonstrated a 20 percent reduction in major adverse cardiovascular events (MACEs) for semaglutide 2.4mg (Wegovy ® ) compared to a placebo. “People living with obesity have an increased risk of cardiovascular disease but to date, there are no approved weight management medications proven to deliver effective weight management while also reducing the risk of heart attack, stroke or cardio
MedCity News
AUGUST 10, 2023
Only 44% of Medicare Advantage enrollees said they “fully understand” their plan, while 50% said they “somewhat understand” it and 6% said they don’t understand it, according to a recent survey.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Copyright Clearance Center
AUGUST 8, 2023
The post Will Building LLMs Become the New Revenue Driver for Academic Publishing? appeared first on Copyright Clearance Center.
Fierce Pharma
AUGUST 9, 2023
AstraZeneca is often at the forefront when it comes to sustainability efforts among pharma companies. Now, the British drugmaker is doubling down on its clean energy commitments in Sweden.
Pharmaceutical Technology
AUGUST 8, 2023
Jacobio Pharma received breakthrough therapy designation (BTD) for glecirasib to treat pancreatic cancer patients with the KRAS G12C mutation.
MedCity News
AUGUST 11, 2023
While greater operational efficiency and cost control are essential to the success of VBC initiatives, so too is patient engagement. Care coordination and care management are far more difficult – and far less likely to achieve optimal outcomes – without patients who are fully engaged with their providers.
Expert insights. Personalized for you.
246 
Let's personalize your content